Radiopharm Theranostics (RADX) Stock Price, News & Analysis

Company Overview

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

Key Stats

• Today's Range: $5.68 to $6.00
• 50-Day Range: $3.84 to $6.67
• 52-Week Range: $3.50 to $50.82
• Volume: 15,825 shs
• Average Volume: 39,696 shs
• Market Capitalization: $45.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Strong Buy

RADX Stock Analysis - Frequently Asked Questions

How have RADX shares performed this year?

Radiopharm Theranostics' stock was trading at $4.00 at the start of the year. Since then, RADX stock has increased by 43.8% and is now trading at $5.75.

Who are Radiopharm Theranostics' major shareholders?

Top institutional shareholders of Radiopharm Theranostics include Affinity Asset Advisors LLC (0.45%) and PNC Financial Services Group Inc. (0.10%).

How do I buy shares of Radiopharm Theranostics?

Shares of RADX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/06/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: NASDAQ:RADX
• CIK: 1949257
• Web: www.radiopharmtheranostics.com
• Phone: 61-3-9824-5254
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Radiopharm Theranostics: $15.00
• High Price Target: $18.00
• Low Price Target: $12.00
• Potential Upside/Downside: +160.9%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 7,880,000
• Free Float: N/A
• Market Cap: $45.31 million
• Optionable: N/A
• Beta: N/A